The company is now seeking commercial partners in Brazil to make the Iona test available in the country.
Adam Wolfberg argued that while corporate conflicts are widely discussed, physicians also have financial conflicts that can bias them against new technology.
The China Food and Drug Administration had also previously accredited both the NIFTY test and the BGISEQ sequencing platform.
The Chinese Academy of Sciences-led team said the approach could lead to a therapeutic strategy for human aneuploidy diseases involving additional chromosomes.
In a study involving almost 23,000 women, DNA reflex testing detect 95 percent of trisomies while avoiding recalls.
Denmark-based Arcedi would like to commercialize its technology through a major diagnostic company.
Several commercial NIPT providers in the US said they are planning to participate in the new program.
The company says Panorama is the only NIPT that can tell whether twins are identical or fraternal, which can impact the clinical management of a pregnancy.
Under the terms of the deal, Dahui Biotech will distribute Devyser's prenatal aneuploidy diagnostic test kits in China.
A UCLA group and spinout FetoLumina Technologies are working on a clinical assay for noninvasive prenatal diagnostics.
CNN reports that researchers have tied a new variant to opioid addiction risk.
Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.
An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.
In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.